Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
December 1, 2015
Arthur N. Brodsky, Ph.D.
Elotuzumab (Empliciti) is the second antibody for myeloma approved in just two weeks.
, multiple myeloma
May 7, 2014
| Michelle Liew
Join Dr. Hearn Jay Cho on May 15 for a discussion on current treatment options for patients with this hematologic cancer.
cancer immunotherapy, multiple myeloma, webinar